December 14, 2020 11:04 AM ESTUpdated 02:31 PM

News briefing: Arvinas shares double on interim data for two cancer programs; UK biopharma snaps up oncology CRO

Max Gelman

Senior Editor

Conner Mitchell

Arvinas $ARVN has new data out on two of its protein degrader programs, and investors seemed thrilled with the news Monday morning as shares doubled …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

News briefing: Arvinas shares double on interim data for two cancer programs; UK biopharma snaps up oncology CRO

Max Gelman

Senior Editor

Conner Mitchell

Sign up to read this article for free.

Trump taps Johns Hopkins researcher Marty Makary to lead the FDA; also names CDC, surgeon general picks

FDA approves BridgeBio's heart disease drug, setting up competition with Pfizer, Alnylam

ADC biotech Adcendo nabs $135M Series B as it enters the clinic

Drug or biologic? An Eli Lilly lawsuit could impact weight loss drug compounders

For CDC, Trump picks Dave Weldon, a former congressman who pushed for vaccine injury claims

From vaccines to psychedelics, five drugmakers on what could change under a Trump administration

News brief­ing: Arv­inas shares dou­ble on in­ter­im da­ta for two can­cer pro­grams; UK bio­phar­ma snaps up on­col­o­gy CRO

Senior Editor

Sign up to read this article for free.

more like this

News briefing: Arvinas shares double on interim data for two cancer programs; UK biopharma snaps up oncology CRO